Search
Outlook Therapeutics Inc
OTLKAdd to Watchlist
0.513USD
-0.006-1.16%
Close 10-26 16:00（ET）
124.89MMarket Cap
LossP/E TTM
Outlook Therapeutics Inc (OTLK) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Outlook Therapeutics Inc in the past month.
Buy
0 Strong Buy
2 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
5.025USD+929.29%
OTLK Analyst Recommendation Trends
In the current month, OTLK has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. OTLK average Analyst price target in the last month is 5.025.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
3
3
3
4
OTLK Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Biontech SE
BNTX
4
12
8
0
0
24
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, OTLK EPS is projected to reach -0.057 in FY2026Q4, following reported EPS of -0.149 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.17
-0.12
-0.09
-0.06
-0.05
Actual
-0.38
-0.05
-0.15
--
--
Surprise
-120.96%
+54.66%
-71.44%
--
--
FAQs
What is Outlook Therapeutics Inc's expected revenue for the next quarter?
Outlook Therapeutics Inc's expected revenue is 3.25M.
What is Outlook Therapeutics Inc's price target?
Analysts forecast that Outlook Therapeutics Inc's price target is USD 5.03, with the highest forecast at USD 10.50 and the lowest forecast at USD 1.60.
How have Outlook Therapeutics IncOTLK's recent earnings per share performed?
The market expectation was USD -0.15, while Outlook Therapeutics IncOTLK's earnings per share (EPS) for the previous quarter was USD -0.05. EPS for the next quarter is expected at USD -0.06.
What is the analyst rating for Outlook Therapeutics Inc?
Based on the ratings of Outlook Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.